January 11, 2021 – Abbott (Abbott Park, IL) received FDA 510(k) clearance for the first rapid handheld traumatic brain injury (TBI) blood test, which will help clinicians assess individuals with suspected mild TBIs, including concussions.
The test will run on Abbott’s handheld i-STAT Alinity™ platform. Tests results are available within 15 minutes after plasma is placed in the test cartridge, the company says.
This test measures specific proteins present in the blood after a TBI (traumatic brain injury). A negative result on this test can be used to rule out the need for a head CT scan, a common tool used to diagnose concussion. For those who test positive, this test result complements CT scans to help clinicians evaluate whether someone has a TBI.
The test requires a small blood sample drawn from the arm, from which plasma is extracted with a centrifuge and applied to the test’s cartridge. The cartridge is then inserted into the handheld instrument.
Abbott is also working on a whole blood test, which would eliminate the need for separation of plasma and could be used at the patient’s side in a healthcare setting. The company’s vision for the future is a 15-minute, portable test that can be used outside the traditional healthcare setting where people experience head injuries and need a quick evaluation, like sporting events.
Abbott has also received FDA breakthrough designation – which speeds assessment of tests through increased FDA interaction – for a TBI test that would run on its Alinity i and ARCHITECT core laboratory instruments. This is part of Abbott’s strategy to ensure that its tests are available both in the lab and in other settings where people need immediate answers and care.